Suppr超能文献

Wnt5a 诱导 ROR1 招募 DOCK2 以激活慢性淋巴细胞白血病中的 Rac1/2。

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.

机构信息

Moores Cancer Center and.

Section of Cell and Developmental Biology, University of California, San Diego, La Jolla, CA; and.

出版信息

Blood. 2018 Jul 12;132(2):170-178. doi: 10.1182/blood-2017-12-819383. Epub 2018 Apr 20.

Abstract

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic protein expressed on chronic lymphocytic leukemia (CLL) that can serve as a receptor for Wnt5a, which can promote leukemia cell migration, proliferation, and survival. We found Wnt5a could induce ROR1 to complex with DOCK2 (dedicator of cytokinesis 2) and induce activation of Rac1/2; these effects could be blocked by cirmtuzumab, a humanized anti-ROR1 monoclonal antibody. We find that silencing DOCK2 specifically impaired the capacity of Wnt5a to induce activation of Rac1/2 or enhance CLL cell proliferation. We generated truncated forms of ROR1 and found the cytoplasmic proline-rich domain (PRD) of ROR1 was required for Wnt5a to induce ROR1 to complex with DOCK2 and activate Rac1/2 in the CLL cell-line MEC1. We introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1-PRD at potential binding sites for the Src-homology 3 domain of DOCK2. In contrast to wild-type ROR1, or other ROR1 P→A variants, ROR1 was unable to recruit DOCK2 in response to Wnt5a. Moreover, unlike MEC1 cells transfected with wild-type ROR1 or ROR1 with P→A substitutions at positions 784, 826, or 841, MEC1 cells transfected to express ROR1 did not have a growth advantage over MEC1 cells that do not express ROR1. This study reveals that the recruitment of DOCK2 may be critical for the capacity of Wnt5a to enhance CLL proliferation, which may contribute to the observed increased tendency for disease progression in patients who have CLL cells that express high levels of ROR1.

摘要

受体酪氨酸激酶样孤儿受体 1(ROR1)是一种在慢性淋巴细胞白血病(CLL)上表达的癌胚蛋白,它可以作为 Wnt5a 的受体,促进白血病细胞迁移、增殖和存活。我们发现 Wnt5a 可以诱导 ROR1 与 DOCK2(胞质分裂促进因子 2)复合物形成,并诱导 Rac1/2 的激活;这些作用可以被 cirmtuzumab(一种人源化抗 ROR1 单克隆抗体)阻断。我们发现,沉默 DOCK2 特异性地削弱了 Wnt5a 诱导 Rac1/2 激活或增强 CLL 细胞增殖的能力。我们生成了 ROR1 的截断形式,发现 ROR1 的细胞质富含脯氨酸结构域(PRD)是 Wnt5a 诱导 ROR1 与 DOCK2 复合物形成并激活 CLL 细胞系 MEC1 中的 Rac1/2 所必需的。我们在 ROR1-PRD 中潜在的 DOCK2 Src 同源 3 结构域结合位点上将脯氨酸(P)突变为丙氨酸(A),引入单个氨基酸取代。与野生型 ROR1 或其他 ROR1 P→A 变体不同,ROR1 无法响应 Wnt5a 招募 DOCK2。此外,与转染野生型 ROR1 或 ROR1 中的 P→A 取代位于 784、826 或 841 位的 MEC1 细胞不同,表达 ROR1 的 MEC1 细胞相对于不表达 ROR1 的 MEC1 细胞没有生长优势。这项研究揭示了 DOCK2 的募集可能对于 Wnt5a 增强 CLL 增殖的能力至关重要,这可能有助于解释在表达高水平 ROR1 的 CLL 细胞患者中观察到的疾病进展趋势增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f90d/6043980/a10f9f17891f/blood819383absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验